A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva [erlotinib] or placebo following four cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for...
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2006
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Sep 2006 The expected completion date for this trial is now 1 Jan 2009.
- 06 Sep 2006 New trial record.